Emergex Vaccines Holding Limited, an Abingdon, England, UK-based biotechnology company developing set-point vaccines to prevent serious infectious diseases, secured over US$11m in Series A funding.

Vickers Venture Partners led the round and Dr. Finian Tan, Chairman of Vickers Venture Partners, will join the Emergex Board as a non-executive director.

Proceeds will also support the Universal Influenza and Filovirus programmes through the preclinical stages and early clinical trials.

In parallel, Emergex will continue to identify peptide libraries for a range of infectious disease indications to further expand and diversify its development pipeline.

Founded in 2016 by Professor Thomas Rademacher, CEO, Emergex focuses on developing vaccines that prevent virulent diseases such as Zika, Dengue Fever, Ebola and even pandemic Flu. | To read full story, visit https://startuparound.com/read/1578564008.88723/Emergex-Secures-Over-US$11M-in-Series-A-Funding?ref=audio_experience